Terms: = Lung cancer AND MSN, P26038, 4478, ENSG00000147065 AND Treatment
16 results:
1. Synergistic effect of mesoporous silica nanocarrier-assisted photodynamic therapy and anticancer agent activity on lung cancer cells.
Güleryüz B; Işık A; Gülsoy M
Lasers Med Sci; 2024 Mar; 39(1):91. PubMed ID: 38491201
[TBL] [Abstract] [Full Text] [Related]
2. The inhibition of pancreatic cancer progression by K-Ras-overexpressing mesenchymal stem cell-derived secretomes.
Huo Q; Li K; Sun X; Zhuang A; Minami K; Tamari K; Ogawa K; Fishel ML; Li BY; Yokota H
Sci Rep; 2023 Sep; 13(1):15036. PubMed ID: 37699930
[TBL] [Abstract] [Full Text] [Related]
3. Efficacy and safety of immuno-chemotherapy in patients with advanced non-small-cell lung cancer harboring oncogenic mutations: a multicenter retrospective study.
Hata T; Sakaguchi C; Hirano K; Kobe H; Ishida M; Nakano T; Tachibana Y; Tamiya N; Shiotsu S; Takeda T; Yamada T; Yokoyama T; Tsuchiya M; Nagasaka Y
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2475-2482. PubMed ID: 35737092
[TBL] [Abstract] [Full Text] [Related]
4. A Review on Recent Technologies and Patents on Silica Nanoparticles for cancer treatment and Diagnosis.
Gupta A; Kushwaha SS; Mishra A
Recent Pat Drug Deliv Formul; 2020; 14(2):126-144. PubMed ID: 32928094
[TBL] [Abstract] [Full Text] [Related]
5. Folic acid (FA)-conjugated mesoporous silica nanoparticles combined with MRP-1 siRNA improves the suppressive effects of myricetin on non-small cell lung cancer (NSCLC).
Song Y; Zhou B; Du X; Wang Y; Zhang J; Ai Y; Xia Z; Zhao G
Biomed Pharmacother; 2020 May; 125():109561. PubMed ID: 32106385
[TBL] [Abstract] [Full Text] [Related]
6. Oral glutamine supplements reduce concurrent chemoradiotherapy-induced esophagitis in patients with advanced non-small cell lung cancer.
Chang SC; Lai YC; Hung JC; Chang CY
Medicine (Baltimore); 2019 Feb; 98(8):e14463. PubMed ID: 30813149
[TBL] [Abstract] [Full Text] [Related]
7. Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex.
Zhao R; Li T; Zheng G; Jiang K; Fan L; Shao J
Biomaterials; 2017 Oct; 143():1-16. PubMed ID: 28755539
[TBL] [Abstract] [Full Text] [Related]
8. A smart pH-responsive nano-carrier as a drug delivery system for the targeted delivery of ursolic acid: suppresses cancer growth and metastasis by modulating P53/MMP-9/PTEN/CD44 mediated multiple signaling pathways.
Jiang K; Chi T; Li T; Zheng G; Fan L; Liu Y; Chen X; Chen S; Jia L; Shao J
Nanoscale; 2017 Jul; 9(27):9428-9439. PubMed ID: 28660943
[TBL] [Abstract] [Full Text] [Related]
9. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
Roskoski R
Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
[TBL] [Abstract] [Full Text] [Related]
10. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
He Y; Su Z; Xue L; Xu H; Zhang C
J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
[TBL] [Abstract] [Full Text] [Related]
11. Ceritinib: a new tyrosine kinase inhibitor for non-small-cell lung cancer.
Cooper MR; Chim H; Chan H; Durand C
Ann Pharmacother; 2015 Jan; 49(1):107-12. PubMed ID: 25258420
[TBL] [Abstract] [Full Text] [Related]
12. Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA.
Taratula O; Garbuzenko OB; Chen AM; Minko T
J Drug Target; 2011 Dec; 19(10):900-14. PubMed ID: 21981718
[TBL] [Abstract] [Full Text] [Related]
13. Targeted radiotherapy of bone malignancies.
Jansen DR; Krijger GC; Kolar ZI; Zonnenberg BA; Zeevaart JR
Curr Drug Discov Technol; 2010 Dec; 7(4):233-46. PubMed ID: 21034411
[TBL] [Abstract] [Full Text] [Related]
14. Carboplatin-epirubicin regimen for the treatment of hepatoblastoma.
Blouin P; Brugières L; Tabone MD; Leverger G; Rubie H; Branchereau S; De Kraker J
Pediatr Blood Cancer; 2004 Feb; 42(2):149-54. PubMed ID: 14752879
[TBL] [Abstract] [Full Text] [Related]
15. Stenting as first option for endovascular treatment of malignant superior vena cava syndrome.
Lanciego C; Chacón JL; Julián A; Andrade J; López L; Martinez B; Cruz M; García-García L
AJR Am J Roentgenol; 2001 Sep; 177(3):585-93. PubMed ID: 11517051
[TBL] [Abstract] [Full Text] [Related]
16. Acute effects of combined photodynamic therapy and hyperbaric oxygenation in lung cancer--a clinical pilot study.
Tomaselli F; Maier A; Sankin O; Anegg U; Stranzl U; Pinter H; Kapp K; Smolle-Jüttner FM
Lasers Surg Med; 2001; 28(5):399-403. PubMed ID: 11413551
[TBL] [Abstract] [Full Text] [Related]
